Published in Oncogene on July 17, 2006
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol (2006) 2.16
Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat Res (2008) 1.61
PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med (2011) 1.33
ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology (2011) 1.26
ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci (2010) 1.23
Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer (2010) 1.23
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2. Nucleic Acids Res (2013) 1.01
Hypoxia selectively activates the CREB family of transcription factors in the in vivo lung. Am J Respir Crit Care Med (2008) 0.97
Activating transcription factor 3 and the nervous system. Front Mol Neurosci (2012) 0.93
Expression and clinical significance of activating transcription factor 3 in human breast cancer. Iran J Basic Med Sci (2013) 0.81
Protective effect of N-acetylcysteine on liver damage during chronic intrauterine hypoxia in fetal guinea pig. Reprod Sci (2012) 0.80
Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. Pigment Cell Melanoma Res (2014) 0.80
ATF3 Mediates Anti-Cancer Activity of Trans-10, cis-12-Conjugated Linoleic Acid in Human Colon Cancer Cells. Biomol Ther (Seoul) (2015) 0.80
Modulation of ozone-sensitive genes in alpha-tocopherol transfer protein null mice. Inhal Toxicol (2010) 0.79
TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth. Oncotarget (2016) 0.76
Age-related brain expression and regulation of the chemokine CCL4/MIP-1β in APP/PS1 double-transgenic mice. J Neuropathol Exp Neurol (2014) 0.75
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (1995) 17.76
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell (1994) 16.30
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev (1998) 12.48
Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem (1995) 9.56
Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (2000) 8.56
Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science (1995) 7.87
Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science (1995) 7.37
MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol (1996) 6.91
cPLA2 is phosphorylated and activated by MAP kinase. Cell (1993) 6.61
Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med (2000) 6.32
Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol (1998) 6.28
Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science (1994) 6.07
Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J (1996) 6.07
The marketplace in health care reform. The demographic limitations of managed competition. N Engl J Med (1993) 5.90
Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl) (1996) 5.77
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ (2000) 5.45
Integration of MAP kinase signal transduction pathways at the serum response element. Science (1995) 5.45
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Posterior cortical atrophy. Arch Neurol (1988) 5.39
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature (1997) 5.29
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science (2000) 5.20
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet (1993) 5.00
A mammalian scaffold complex that selectively mediates MAP kinase activation. Science (1998) 4.78
A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (1997) 4.56
The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron (1999) 4.51
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Community-level comparisons between the grocery store environment and individual dietary practices. Prev Med (1991) 4.45
Defective T cell differentiation in the absence of Jnk1. Science (1998) 4.40
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 4.20
Transcription factor ATF interacts with the TATA factor to facilitate establishment of a preinitiation complex. Cell (1988) 4.15
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
Regulation of JNK signaling by GSTp. EMBO J (1999) 4.06
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
hBD-1: a novel beta-defensin from human plasma. FEBS Lett (1995) 3.79
Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity (1998) 3.70
Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem (1995) 3.69
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
An osmosensing signal transduction pathway in mammalian cells. Science (1994) 3.49
Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding: prediction and rational design. Genes Dev (1993) 3.39
The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem (1996) 3.38
Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J Biol Chem (1991) 3.37
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
A JNK signal transduction pathway that mediates morphogenesis and an immune response in Drosophila. Genes Dev (1996) 3.21
Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem (1998) 3.21
The JIP group of mitogen-activated protein kinase scaffold proteins. Mol Cell Biol (1999) 3.18
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells. J Immunol (1997) 3.07
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J (1999) 2.96
Signal transduction within the nucleus by mitogen-activated protein kinase. J Biol Chem (1992) 2.93
Age-related changes in cortical blood flow activation during visual processing of faces and location. J Neurosci (1994) 2.92
Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol (1994) 2.90
PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther (1999) 2.90
The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem (1994) 2.84
Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Trends Biochem Sci (1998) 2.83
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus. J Cell Biol (1993) 2.74
HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J (2001) 2.73
Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol (1996) 2.72
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J (1999) 2.70
WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in C. elegans. Cell (1999) 2.69
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol (1997) 2.58
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
A conserved p38 mitogen-activated protein kinase pathway regulates Drosophila immunity gene expression. Mol Cell Biol (1998) 2.57
Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J (1998) 2.54
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J (2001) 2.51
Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest (1997) 2.48
MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev (2001) 2.48
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. Proc Natl Acad Sci U S A (1997) 2.46
The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol Cell Biol (1998) 2.44
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J (1998) 2.41
Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10. Mol Cell Biol (1996) 2.41
Base composition of ribosomal RNA precursors in the HeLa cell nucleolus: further evidence of non-conservative processing. J Mol Biol (1968) 2.40
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Differences in sociodemographic, health status, and lifestyle characteristics among American Indians by telephone coverage. Prev Med (1994) 2.37
Tumor-promoting phorbol diesters cause the phosphorylation of epidermal growth factor receptors in normal human fibroblasts at threonine-654. Proc Natl Acad Sci U S A (1985) 2.36
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
JNK is required for effector T-cell function but not for T-cell activation. Nature (2000) 2.33
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science (1997) 2.25
Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature (1994) 2.24
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci U S A (1997) 2.21